Fig. 1 · Structure

Documents & Downloads

Nilotinib (AMN-107)

Cat. No. A10644 CAS 641571-10-0

Bcr-Abl inhibitor

Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM.

In Stock

Publications for Nilotinib

2 publications citing this product

  1. Rami Shinnawi, .et al. , Stem Cell Reports, 2015, Oct 13; 5(4): 582-596 PMID: 26372632
  2. Tetsuya Saita, .et al. , Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In a P190 Bcr/Abl leukemia mouse model, representative lymphoma samples showed lower Bcr/Abl and Crkl phosphorylation 2 h after nilotinib dosing than 23 h after dosing, consistent with transient pathway suppression. The comparison involved different mice and did not establish a biochemical IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Bcr-Abl (Murine myeloid progenitor cells) <30 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 6.63 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 23521020]
BaF3 IC50 > 1 μM Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay [PMID: 26195136]
BaF3 GI50 > 10 μM Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 IC50 > 100 nM Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay [PMID: 34011155]
BaF3 IC50 0.003 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 GI50 0.004 μM Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 IC50 0.0095 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 GI50 0.017 μM Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 GI50 0.021 μM Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 IC50 0.022 μM Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 GI50 0.023 μM Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 GI50 0.025 μM Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 GI50 0.0546 μM Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay [PMID: 26789553]
BaF3 IC50 0.12 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 IC50 0.12 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 IC50 0.13 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 IC50 0.15 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 IC50 0.16 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]
BaF3 IC50 0.17 μM Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay [PMID: 23301703]

19 records · Scroll to view more

In Vitro Studies

In ArcLight-expressing human iPSC-derived cardiomyocytes, 1 μM nilotinib for 1 h prolonged optical APD90 from 470 ± 36 to 821 ± 79 ms (mean ± SEM; n = 17 cells across three independent experiments; p < 0.01). Early afterdepolarizations occurred in 18% of cells. These results identify an electrophysiological liability in this cellular model. [2]

Nilotinib alters action potentials in human iPSC-derived cardiomyocytes

Cell-based study · ArcLight-expressing human induced pluripotent stem cell-derived cardiomyocytes [2]

At 1 μM, nilotinib prolonged optical APD90 and produced early afterdepolarizations. This is a cellular safety-pharmacology observation, not a clinical risk estimate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Optical action-potential duration at 90% repolarizationAPD90 Baseline 470 ± 36 ms; nilotinib 821 ± 79 ms; mean ± SEM; n = 17 cells in three independent experiments; p < 0.01[2]
Cells developing early afterdepolarizationsFrequency 18% of ArcLight-hiPSC-CMs[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
1 hr in Results and Figure 4D; general optical-imaging methods specify 60–90 min for nilotinib.
Method
Application to Tyrode’s solution followed by optical recording.
Vehicle
DMSO; identical 0.1% DMSO used as vehicle controls.
Reported limits
Exact salt/form, catalog number and lot are not specified in the read main text; supplemental methods were not read. No vehicle-only numerical APD90 result is supplied in the adopted main-text result/figure.
Methods and source locations

Compound reported in the paper: Nilotinib; Compound label in the paper: Nilotinib (Adooq Bioscience)

Applicable to the named research compound. Does not establish free-base versus salt equivalence or validate a present A10644 lot.

Results: Drug Testing Using ArcLight-hiPSC-CMs; Figure 4D and caption; Experimental Procedures: Pharmacological Studies, Optical Imaging, Statistical Analysis

Optical action-potential duration at 90% repolarization: ArcLight optical recordings; paired Student’s t test against baseline. — Results: Drug Testing Using ArcLight-hiPSC-CMs; Figure 4D and caption; Experimental Procedures: Pharmacological Studies, Optical Imaging, Statistical Analysis

Cells developing early afterdepolarizations: ArcLight optical recordings; frequency reported in Results. — Results: Drug Testing Using ArcLight-hiPSC-CMs; Figure 4D and caption; Experimental Procedures: Pharmacological Studies, Optical Imaging, Statistical Analysis

In Vivo Studies

In mice bearing P190 Bcr/Abl lymphoblastic leukemia, oral nilotinib at 75 mg/kg daily prolonged survival versus vehicle. Disease control was incomplete: five of seven treated mice died during treatment, and the two remaining mice died of leukemia after treatment withdrawal. [1]

Survival and pathway readouts in a P190 Bcr/Abl leukemia transplant model

Animal study · Six-week-old male C57Bl/6J mice bearing 8093 P190 Bcr/Abl lymphoblastic leukemia [1]

Daily oral nilotinib prolonged survival versus vehicle without eradicating leukemia. Representative lymphoma samples showed lower Bcr/Abl phosphotyrosine and phosphorylated Crkl signals 2 h versus 23 h after dosing; these are different mice, not a paired time course.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival relative to vehicleSurvival comparison n = 7 nilotinib; n = 8 vehicle. Results: p < 0.05; Figure 2 caption: p < 0.01. Five of seven treated mice died during treatment; the two survivors died 8 and 14 days after withdrawal.[1]
Bcr/Abl phosphotyrosine and Crkl phosphorylation in lymphoma tissueQualitative immunoblot comparison Representative S9 (2 h after dosing) showed lower Bcr/Abl phosphotyrosine and less phosphorylated Crkl than S5 (23 h).[1]

Conditions shared by the study groups

Route
Oral, fed in peanut butter/vegetable oil mixture.
Frequency
Daily
Treatment course
Started five days after transplantation. Methods state cessation 50 days after day 1; Results state day 51 after transplantation. Exact cessation convention remains unresolved.
Vehicle
8 parts peanut butter and 2 parts vegetable oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nilotinib (n = 7)
75 mg/kg
Vehicle-treated mice (n = 8)Survival prolonged; five of seven died during treatment. Two remaining mice died of leukemia 8 and 14 days after treatment withdrawal, as reported in Results.[1]
Vehicle (n = 8)Concurrent nilotinib group (n = 7)All vehicle-group mice died; Results describe moribund animals within three weeks.[1]
Nilotinib (n = 7)
Model: Six-week-old male C57Bl/6J mice bearing 8093 P190 Bcr/Abl lymphoblastic leukemia
Reported limits: Exact salt and lot not specified; no precise course reconciled across Results and Methods.
Vehicle (n = 8)
Model: Six-week-old male C57Bl/6J mice bearing 8093 P190 Bcr/Abl lymphoblastic leukemia
Reported limits: Exact salt and lot not specified; no precise course reconciled across Results and Methods.
Methods and source locations

Compound reported in the paper: Nilotinib (AMN107); Compound label in the paper: Nilotinib supplied by Novartis Pharmaceuticals

Named-compound preclinical evidence only; salt-specific exposure, present Adooq material and human efficacy are not established.

Results: Treatment with nilotinib in a transplant model; Figure 2 and caption; Methods: Treatment with nilotinib in a transplant model; Statistical analysis; Results: Effect of nilotinib on Bcr/Abl tyrosine kinase activity; Figure 4A-D and caption; Methods: Western blot analysis

Survival relative to vehicle: Survival analysis; log-rank test. No median or exact p-value inferred from the curve. — Results: Treatment with nilotinib in a transplant model; Figure 2 and caption; Methods: Treatment with nilotinib in a transplant model; Statistical analysis

Bcr/Abl phosphotyrosine and Crkl phosphorylation in lymphoma tissue: Figure 4A-D immunoblots include total Bcr/Bcr-Abl and GAPDH controls. Representative between-mouse comparison, with no densitometric effect size or untreated tissue lane in this figure. — Results: Effect of nilotinib on Bcr/Abl tyrosine kinase activity; Figure 4A-D and caption; Methods: Western blot analysis

Nilotinib (n = 7) · Results: Treatment with nilotinib in a transplant model; Figure 2 and caption; Methods: Treatment with nilotinib in a transplant model; Statistical analysis

Vehicle (n = 8) · Results: Treatment with nilotinib in a transplant model; Figure 2 and caption; Methods: Treatment with nilotinib in a transplant model; Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 641571-10-0
Applications Bcr-Abl inhibitor
Formula C28H22F3N7O
Molecular Weight 529.5
Synonyms AMN-107
SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 26 mg/mL (49.09 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
4% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Pavinder Kaur, Niklas Feldhahn, Bin Zhang, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia Molecular Cancer (2007). PMID: 17958915 DOI: 10.1186/1476-4598-6-67 Source material
  2. [2] Rami Shinnawi, Irit Huber, Leonid Maizels, et al. Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters Stem Cell Reports (2015). PMID: 26372632 DOI: 10.1016/j.stemcr.2015.08.009 Source material

Publications

2 publications citing this product

  1. Rami Shinnawi, .et al. , Stem Cell Reports, 2015, Oct 13; 5(4): 582-596 PMID: 26372632
  2. Tetsuya Saita, .et al. , Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026

Added to your cart

View Cart Checkout
Loading...